ES2178048T3 - Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis. - Google Patents

Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.

Info

Publication number
ES2178048T3
ES2178048T3 ES98101081T ES98101081T ES2178048T3 ES 2178048 T3 ES2178048 T3 ES 2178048T3 ES 98101081 T ES98101081 T ES 98101081T ES 98101081 T ES98101081 T ES 98101081T ES 2178048 T3 ES2178048 T3 ES 2178048T3
Authority
ES
Spain
Prior art keywords
treatment
rifaximine
cryptosporidiosis
diarrhea
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98101081T
Other languages
English (en)
Inventor
Patrizio Ferrari
Antonella Ferrieri
Pietro Caramello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Application granted granted Critical
Publication of ES2178048T3 publication Critical patent/ES2178048T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

EL OBJETO DE LA PRESENTE INVENCION ES EL USO DE CANTIDADES TERAPEUTICAMENTE EFICACES DE RIFAMIXINA Y DE COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN, EN EL TRATAMIENTO DE LA SINTOMATOLOGIA DIARREICA EN CASOS DE CRIPTOSPORIDIOSIS EN PACIENTES QUE PADECEN FORMAS GRAVES DE INMUNODEPRESION, POR EJEMPLO PACIENTES QUE PADECEN SIDA O NEOPLASIAS MALIGNAS, O SOMETIDOS A TRANSPLANTES O TRATADOS CON AGENTES QUIMIOTERAPEUTICOS O INMUNOSUPRESORES.
ES98101081T 1997-02-14 1998-01-22 Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis. Expired - Lifetime ES2178048T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.

Publications (1)

Publication Number Publication Date
ES2178048T3 true ES2178048T3 (es) 2002-12-16

Family

ID=11341939

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98101081T Expired - Lifetime ES2178048T3 (es) 1997-02-14 1998-01-22 Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.

Country Status (12)

Country Link
US (1) US5886002A (es)
EP (1) EP0858804B1 (es)
JP (1) JP4848083B2 (es)
KR (1) KR100436243B1 (es)
CN (1) CN1115146C (es)
AT (1) ATE218342T1 (es)
DE (1) DE69805672T2 (es)
DK (1) DK0858804T3 (es)
ES (1) ES2178048T3 (es)
HU (1) HU224592B1 (es)
IT (1) IT1290679B1 (es)
PT (1) PT858804E (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
EA200501710A1 (ru) * 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые карбоновые кислоты
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
MX2009001342A (es) * 2006-08-02 2009-08-31 Salix Pharmaceuticals Inc Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
AU2009297562B2 (en) 2008-09-26 2015-04-23 Alfasigma S.P.A. Agent for preventing and/or treating functional gastrointestinal disorder
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) * 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
WO2016138118A1 (en) * 2015-02-26 2016-09-01 Jaguar Animal Health, Inc. Use of croton- or calophyllum-derived proanthocyanidin polymers or botanical extracts in combination with rifaximin for the treatment of diarrhea in non-human animals
AU2016274311A1 (en) * 2015-06-10 2018-01-18 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
ES2979135T3 (es) 2016-10-14 2024-09-24 Cipla Ltd Composiciones farmacéuticas que comprenden rifaximina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Also Published As

Publication number Publication date
HU9800115D0 (en) 1998-03-30
EP0858804A1 (en) 1998-08-19
IT1290679B1 (it) 1998-12-10
JP4848083B2 (ja) 2011-12-28
ITBO970064A0 (it) 1997-02-14
ATE218342T1 (de) 2002-06-15
HU224592B1 (hu) 2005-11-28
DE69805672D1 (de) 2002-07-11
KR19980071348A (ko) 1998-10-26
EP0858804B1 (en) 2002-06-05
JPH10226645A (ja) 1998-08-25
CN1115146C (zh) 2003-07-23
CN1214244A (zh) 1999-04-21
DE69805672T2 (de) 2003-01-23
ITBO970064A1 (it) 1998-08-14
PT858804E (pt) 2002-10-31
KR100436243B1 (ko) 2004-08-25
US5886002A (en) 1999-03-23
HUP9800115A1 (hu) 1999-06-28
DK0858804T3 (da) 2002-07-08
HUP9800115A3 (en) 2000-04-28

Similar Documents

Publication Publication Date Title
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ES2154287T3 (es) Procedimiento para modificar el crecimiento de los pelos y/o de los cabellos y composiciones utilizables a este efecto.
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
GT199900203A (es) Composiciones de celecoxib.
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
ES2157601T3 (es) Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple.
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
PT858804E (pt) Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose
SE9701161D0 (sv) New use I
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
ATE289293T1 (de) Substituierte aminoalkylamid-derivate als antagonisten des follikel-stimulierenden hormons
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
ES2149279T3 (es) Sistema terapeutico para el tratamiento de la psoriasis.
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
ES2173911T3 (es) Uso de glicosidos en vitamina d para el tratamiento o prevencion de la osteoporosis.
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
ES2106319T3 (es) Uso de lactoferrina en la fabricacion de un medicamento para el tratamiento del reumatismo.
ES2159357T3 (es) Derivados terpenoides (sarcodictinas) utiles como agentes antitumorales.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.